ImmunoCellular Therapeutics (IMUC.OB) is developing cellular immunotherapies for the treatment of brain cancer and monoclonal antibodies to diagnose and treat several different cancers. The Company is developing a stem cell cancer vaccine (ICT-121) which targets a protein marker called CD133 which is typically expressed only on cancer stem cells and not on normal cells. ETF Innovators Global Stem Cell and Regenerative Medicine Index: http://biomedreports.com/health-indexes.html C (...) [More...]